The similar benefit using pharmacological DNM2 inhibitors [74, 75, 82, 84–88] or DNM2 gene silencing demonstrates the requirement of the DNM2 GTPase activity in the phenotypes occurring in these cancer cells. The gene discussed is DNM2; the disease is cancer.